ENTITY

Jiangsu Hengrui Pharmaceuticals (1276 HK)

316
Analysis
Health Care • China
Jiangsu Hengrui Pharmaceuticals is a global biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of innovative and high-quality drugs. The company focuses on therapeutic areas including oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. It was founded in 1970 and is headquartered in Lianyungang, Jiangsu, China.
more
•28 Oct 2025 01:37

SANY Heavy Industry H Share Listing (6031 HK): Trading Debut

Sany Heavy raised US$1.7 billion in gross proceeds. Sany's international oversubscription rates were above the median of recent large AH listings....

Logo
914 Views
Share
bullish•Seres Group
•27 Oct 2025 15:52

Seres Group H Share Listing (9927 HK): Valuation Insights

Seres Group has launched an H Share listing to raise US$1.7 billion. The proposed AH discount of 24.8% implied by the H Share offer price is...

Logo
1k Views
Share
•26 Oct 2025 10:15

A-H Premium Weekly (Oct 24th): China Oilfield Services, Cgn Power, Anhui Expressway, Air China

We analyzed A-H premium changes in the past week and highlight A-H premium changes for China Oilfield Services, Cgn Power, Anhui Expressway, Air...

Logo
384 Views
Share
•23 Oct 2025 09:48

Horizon Robotics IPO Lockup - Last of the Lockups, Large Pre-IPO Investors Still Holding On

Horizon Robotics (9660 HK) raised around US$800m in its Hong Kong IPO in October 2024. Its first set of lockups expired in April 2025. The next one...

Logo
1.5k Views
Share
•21 Oct 2025 16:16

SANY Heavy Industry H Share Listing (6031 HK): Valuation Insights

The proposed AH discount of 17.2% to 13.1% (based on the 17 October A Share price) is attractive, and I would participate in the H Share listing.

Logo
1k Views
Share
x